These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Safe duration of postoperative monitoring for malignant hyperthermia patients administered non-triggering anaesthesia: an update. Barnes C; Stowell KM; Bulger T; Langton E; Pollock N Anaesth Intensive Care; 2015 Jan; 43(1):98-104. PubMed ID: 25579296 [TBL] [Abstract][Full Text] [Related]
3. Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy. Carr AS; Lerman J; Cunliffe M; McLeod ME; Britt BA Can J Anaesth; 1995 Apr; 42(4):281-6. PubMed ID: 7788824 [TBL] [Abstract][Full Text] [Related]
4. Analysis of anaesthesia in patients suspected to be susceptible to malignant hyperthermia before diagnostic in vitro contracture test. Bendixen D; Skovgaard LT; Ording H Acta Anaesthesiol Scand; 1997 Apr; 41(4):480-4. PubMed ID: 9150775 [TBL] [Abstract][Full Text] [Related]
5. Malignant hyperthermia and day stay surgery. Pollock N; Langton E; McDonnell N; Tiemessen J; Stowell K Anaesth Intensive Care; 2006 Feb; 34(1):40-5. PubMed ID: 16494148 [TBL] [Abstract][Full Text] [Related]
6. Evidence of malignant hyperthermia in patients administered triggering agents before malignant hyperthermia susceptibility identified: missed opportunities prior to diagnosis. Chan TY; Bulger TF; Stowell KM; Gillies RL; Langton EE; Street NE; Pollock NA Anaesth Intensive Care; 2017 Nov; 45(6):707-713. PubMed ID: 29137581 [TBL] [Abstract][Full Text] [Related]
7. Use of vecuronium and doxapram in patients susceptible to malignant hyperthermia. Ording H; Fonsmark L Br J Anaesth; 1988 Mar; 60(4):445-9. PubMed ID: 2895665 [TBL] [Abstract][Full Text] [Related]
8. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States. Larach MG; Brandom BW; Allen GC; Gronert GA; Lehman EB Anesth Analg; 2014 Dec; 119(6):1359-66. PubMed ID: 25268394 [TBL] [Abstract][Full Text] [Related]
9. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests]. Mortier W; Breucking E Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201 [TBL] [Abstract][Full Text] [Related]
10. Effect of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia. Sato N; Brum JM; Mitsumoto H; DeBoer GE Can J Anaesth; 1995 Feb; 42(2):158-62. PubMed ID: 7720160 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of 119 anaesthetics received after investigation for susceptibility to malignant hyperthermia. Ording H; Hedengran AM; Skovgaard LT Acta Anaesthesiol Scand; 1991 Nov; 35(8):711-6. PubMed ID: 1763590 [TBL] [Abstract][Full Text] [Related]